Ocular, BioWorld Asia
RSS

Shanghai’s Arctic Vision gets China and Korea rights to Xipere in $35.5M deal with Clearside Biomedical

March 17, 2020

BEIJING – Arctic Vision (Shanghai) Biotechnology Co. Ltd. has in-licensed from Clearside Biomedical Inc. the commercialization and development rights of Xipere for greater China and South Korea.

Bringing glaucoma risk into focus

Multitrait analysis predicts glaucoma susceptibility, progression

January 28, 2020

By John Fox

No Comments

An international collaborative study led by geneticists at the Queensland Institute of Medical Research Berghofer Medical Research Institute (QIMR) in Brisbane, Australia, has used a multivariate approach to develop a polygenic risk score (PRS) for glaucoma.

Bionetix secures $9.33M in series B funding for AML/MDS and glaucoma treatment

January 21, 2020

By Jihyun Kim

No Comments

HONG KONG – Bionetix Inc., of Suwon, South Korea, has secured ₩10.8 billion (US$9.33 million) in series B funding. The biotech, founded in February 2017, has attracted a total of KRW14.7 billion to date. The company will use the funds to advance NTX-301, a therapy for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with epigenetic dysregulation, and NTX-101, a glaucoma treatment.

Australia’s Opthea raises AU$50M to advance OPT-302 to phase III in wet AMD

December 3, 2019

By Tamra Sami

No Comments

PERTH, Australia – On the heels of positive phase IIb data, Opthea Ltd. announced a private placement of AU$50 million (US$33.87 million) from institutional investors in Australia and the U.K. to advance lead candidate OPT-302 to phase III trials in wet AMD.

South Korea approves first four COVID-19 test kits under urgent-use license

BioWorld

HONG KONG – South Korea’s Ministry of Food and Drug Safety (MFDS) recently granted the first urgent-use licenses to four COVID-19 novel coronavirus diagnostic...

Two South Korean COVID-19 kits look overseas, seek FDA approval

BioWorld MedTech

HONG KONG – As the number of COVID-19 confirmed cases and deaths continue to rise globally, South Korea’s focus on testing has attracted international attention....

Noninvasive ventilation options explored for COVID-19, as FDA eases with guidance

BioWorld MedTech

Like so many other ventilator providers in recent days, Resmed Inc. has committed to ramping up production. It aims to triple its ventilator output and multiply...

FDA says yes to NO: Bellerophon Therapeutics wins expanded access approval for inhaled nitric oxide system

BioWorld

DUBLIN—Can high-dose inhaled nitric oxide (NO) make a meaningful contribution to patients with COVID-19 infection? The FDA was sufficiently persuaded by the data...

Antiviral favipiravir effective against COVID-19, China says

BioWorld

Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment by Fujifilm Holdings Corp., have shown "obvious efficacy"...

Ocular, BioWorld Asia
RSS

Shanghai’s Arctic Vision gets China and Korea rights to Xipere in $35.5M deal with Clearside Biomedical

Multitrait analysis predicts glaucoma susceptibility, progression

Bionetix secures $9.33M in series B funding for AML/MDS and glaucoma treatment

Australia’s Opthea raises AU$50M to advance OPT-302 to phase III in wet AMD

Popular Stories

South Korea approves first four COVID-19 test kits under urgent-use license

Two South Korean COVID-19 kits look overseas, seek FDA approval

Noninvasive ventilation options explored for COVID-19, as FDA eases with guidance

FDA says yes to NO: Bellerophon Therapeutics wins expanded access approval for inhaled nitric oxide system

Antiviral favipiravir effective against COVID-19, China says

BioWorld Premium

Ocular, BioWorld Asia RSS

Popular Stories

BioWorld Premium

Ocular, BioWorld Asia
RSS